Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — Sachs European Life Science Forum 2026
9 slides from Expres2ion Biotech Holding Ab's conference presentation, Mar 5, 2026
Slide 1: ES2B-C001: a therapeutic HER2 vaccine designed for durable immune control
March 5 th , 2026 Keith Alexander, CFO ES2B - C001: a therapeutic HER2 vaccine designed for durable immune control STO: EXPRS2 ExpreS2ion Biotech Holding AB Org. Nr. 559033 - 3729
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to u nde rwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company”). Neither shall the presentation or any part of
Slide 3: HER2-Driven Breast Cancer: Durable Control Remains the Gap
HER2 - Driven Breast Cancer: Durable Control Remains the Gap Population and biological context Where durability remains limited • ~2.3M new cases annually 1 • HER2 spectrum (IHC/ISH): Durability CNS Later lines HER2+ HER2 - low HER2 - negative • Progression • Brain • Incremental ~15%2 ~45 - 55% 3 ~3
Slide 4: ES2B-C001: A Novel VLP-Based Multi-Epitope HER2 Immunotherapy
ES2B - C001: A Novel VLP - Based Multi - Epitope HER2 Immunotherapy Built on proprietary ExpreS2 and VLP technologies evaluated in large - scale human studies • VLP multivalent display enhances B - cell activation Full HER2 • Full HER2 ECD presentation drives multi - epitope, extracellular polyclona
Slide 5: Strategic Positioning In HER2-Positive Breast Cancer
Strategic Positioning In HER2 - Positive Breast Cancer Designed to complement current standards Designed for use alongside established HER2 therapies, Combination Strategy including monoclonal antibodies, ADCs, and TKIs, across lines of care Durability and Positioned to enhance long - term immune co
Slide 6: Evidence to Date: Preclinical Tumour Control and Early Phase I Immune Signals
Evidence to Date: Preclinical Tumour Control and Early Phase I Immune Signals Preclinical Tumour Growth Inhibition Phase I (Exploratory): in FVB HER2 Tumour Model (n=10/group) Vaccine - Induced Anti - HER2 λ Light Chain Titers 12,500 ES2B-C001 10 g i.m. ES2B-C001 ES2B 10 g - C001 10i.m.+Montanide
Slide 7: 12–18 Month Data Maturation and Phase II Decision Path
12– 18 Month Data Maturation and Phase II Decision Path ES2B - C001: Phase I Data Maturation and Strategic Next Steps Q1– Q2 2026 Phase I Decision Criteria Decision Gate Interim Phase Ia safety and • Acceptable safety at a biologically • Advance into Phase II in a defined immunogenicity data maturat
Slide 8: ExpreS2ion: One Operating Company, Two Value Pillars
ExpreS2ion: One Operating Company, Two Value Pillars Operating oncology asset + validated platform + minority strategic equity stake Oncology Pipeline (Internal) ExpreS2 Protein Expression Platform 34% Ownership in AdaptVac Primary value driver • 500+ proteins expressed; >90% • Co - founded in 2017;
Slide 9: Q&A
Q&A NASDAQ FN: EXPRS2 Innovative vaccines for a healthier world investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — Sachs European Life Science Forum 2026 on 6ix